GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kazia Therapeutics Ltd (ASX:KZA) » Definitions » Short-Term Debt

Kazia Therapeutics (ASX:KZA) Short-Term Debt : A$0.36 Mil (As of Dec. 2023)


View and export this data going back to 1994. Start your Free Trial

What is Kazia Therapeutics Short-Term Debt?

Kazia Therapeutics's Short-Term Debt for the quarter that ended in Dec. 2023 was A$0.36 Mil.

Kazia Therapeutics's quarterly Short-Term Debt increased from Dec. 2022 (A$0.55 Mil) to Jun. 2023 (A$1.80 Mil) but then declined from Jun. 2023 (A$1.80 Mil) to Dec. 2023 (A$0.36 Mil).

Kazia Therapeutics's annual Short-Term Debt increased from Jun. 2021 (A$0.00 Mil) to Jun. 2022 (A$1.84 Mil) but then declined from Jun. 2022 (A$1.84 Mil) to Jun. 2023 (A$1.80 Mil).


Kazia Therapeutics Short-Term Debt Historical Data

The historical data trend for Kazia Therapeutics's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kazia Therapeutics Short-Term Debt Chart

Kazia Therapeutics Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 1.84 1.80

Kazia Therapeutics Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 1.84 0.55 1.80 0.36

Kazia Therapeutics Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.


Kazia Therapeutics Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Kazia Therapeutics's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Kazia Therapeutics (ASX:KZA) Business Description

Traded in Other Exchanges
Address
300 Barangaroo Avenue, Level 24, Three International Towers, Sydney, NSW, AUS, 2000
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing innovative anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors.

Kazia Therapeutics (ASX:KZA) Headlines

No Headlines